Beasley David W C
Department of Microbiology and Immunology, and Institute for Human Infections and Immunity, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555-0609, USA.
Curr Mol Med. 2005 Dec;5(8):835-50. doi: 10.2174/156652405774962272.
Since the mid-1990s, West Nile virus (WNV) has emerged as a significant agent of arboviral encephalitis in several regions of the world. In 1999, WNV was introduced into the northeastern United States and was associated with an outbreak of encephalitis affecting humans, birds and horses. Subsequently, the virus has spread across the country, and across southern Canada, and in 2002 and 2003 was associated with the largest outbreaks of arboviral encephalitis recorded in the Western hemisphere. Interestingly, the more recent spread of WNV into Mexico, Central America and the Caribbean has not been associated with the high levels of clinical disease observed in North America. This review addresses the most recent results from studies investigating the molecular biology and evolution of WNV, as well as progress in the development of diagnostic and therapeutic reagents.
自20世纪90年代中期以来,西尼罗河病毒(WNV)已在世界多个地区成为虫媒病毒性脑炎的重要病原体。1999年,WNV传入美国东北部,并与一场影响人类、鸟类和马匹的脑炎疫情相关联。随后,该病毒已蔓延至美国全国以及加拿大南部,并在2002年和2003年与西半球有记录以来最大规模的虫媒病毒性脑炎疫情相关。有趣的是,WNV最近向墨西哥、中美洲和加勒比地区的传播并未伴随在北美所观察到的高水平临床疾病。本综述阐述了有关WNV分子生物学和进化研究的最新结果,以及诊断和治疗试剂开发方面的进展。